Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Earnings for Bachem Holding AG (BANB.SW)
Earnings in 2023 (TTM): $140.64 M
According to Bachem Holding AG's latest financial reports the company's current earnings (TTM) are $140.64 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Bachem Holding AG
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $140.64 M | $126.66 M |
| 2022 | $126.9 M | $114 M |
| 2021 | $148.77 M | $129.85 M |
| 2020 | $102.99 M | $88.39 M |
| 2019 | $68.36 M | $61.33 M |
| 2018 | $61.86 M | $52.81 M |
| 2017 | $54.76 M | $47.3 M |
| 2016 | $51.96 M | $46.66 M |
| 2015 | $42.21 M | $36.05 M |
| 2014 | $41.15 M | $32.91 M |
| 2013 | $32.72 M | $26.73 M |
| 2012 | $21.94 M | $17.32 M |
| 2011 | $13.86 M | $10.65 M |
| 2010 | $36.21 M | $32.04 M |
| 2009 | $52.37 M | $52.15 M |
| 2008 | $76.59 M | $66.47 M |
| 2007 | $93.1 M | $72.38 M |
| 2006 | $67.35 M | $52.82 M |
| 2005 | $55.84 M | $44.42 M |
| 2004 | $47.68 M | $36.58 M |
| 2003 | $54.96 M | $42.24 M |
| 2002 | $50.6 M | $37.92 M |